Jambor I, et al. - In this multi-institutional trial, IMPROD biparametric magnetic resonance imaging (MRI) (bpMRI)-a previously developed unique MRI acquisition and reporting protocol- was put to test for validation in men with a clinical suspicion of prostate cancer (PCa). IMPROD bpMRI includes T2-weighted imaging and 3 separate diffusion-weighed imaging acquisitions and has an average acquisition time of 15 minutes (no endorectal coil, no intravenous contrast use). Of 364 enrolled men with a clinical suspicion of PCa, 338 completed the study. For significant PCa (SPCa), IMPROD bpMRI yielded 70% (113/161) of accuracy and 95% (71/75) negative predictive value (NPV). In other words, a high NPV for SPCa was shown by IMPROD bpMRI in men with a clinical suspicion of PCa in this prospective clinical trial.